Biomed Israel 2026 abstract

NOGA Therapeutics

www.noga-tx.com

CEO Noam Baumatz

CATEGORY: Biotech/Pharma

SESSION

"Rewriting Biology In Vivo: The Age of Cellular Reprogramming."

Executive Summary / Investment Rational

NOGA Therapeutics is developing precision hematopoietic stem cell gene therapies, beginning with X-linked agammaglobulinemia (XLA). Its lead program, NOGA-102, is an ex vivo BTK gene therapy designed for safe, effective expression. The company's strategy is to use XLA to de-risk biology, establish an in vivo HSC platform, and then expand into common autoimmune diseases with broader market potential.

Core Technology

NOGA's core technology is precision gene expression for HSC gene therapy. In XLA, this means restoring BTK within a therapeutic expression window, avoiding both underexpression and overexpression. The next step is Lent-Me-In, a targeted in vivo HSC platform for integrating gene addition in diseases where durable, regulated expression is required and small-edit approaches are insufficient.

Product Profile/Pipeline

NOGA-102 is the lead ex vivo program for XLA, supported by preclinical data showing precision BTK expression and selective advantage of corrected B cells. The pipeline then expands to in vivo XLA as the platform-establishing step, followed by autoimmune indications beginning with Inflammatory Bowel Disease (IBD) and Systemic Lupus

Erythematosus (SLE), where durable immune reprogramming could open much larger markets.

Business Strategy

NOGA's strategy is to begin with a rare monogenic indication where biology is well defined and development can be focused, then convert that validation into an in vivo platform with broader applicability. This creates a path from an initial product in XLA to a larger immunology franchise addressing common autoimmune diseases with significant commercial potential.

What's Next?

Near term, NOGA is advancing IND-enabling studies for NOGA-102 through its NIH collaboration, with planned regulatory submission and first-in-human study to follow. In parallel, the company is developing Lent-Me-In as an in vivo HSC platform and defining its first broader immunology applications, beginning with in vivo XLA and autoimmune pipeline programs in IBD and SLE.